English

Camp4 Therapeutics Corp

EDGAR

CAMP Quarterly report (10-Q) · filed 2026-08-13

Annual consolidated revenue for 2025: about USD 3.498M, using the latest reported figures. The previous period, 2024, was about USD 652K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

1.78 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 1779000 USD Source

Operating margin

-752.11%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -13380000 USD Source
Revenue: 1779000 USD Source

Operating cash flow

-12.7 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -23700000 USD Source
Operating Cash Flow: -11000000 USD Source

Free cash flow

-12.8 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -23700000 USD Source
Operating Cash Flow: -11000000 USD Source
Capital Expenditure: 129000 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 86.4 million USD 2026-06-30 Source
Exact value

86398000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 51.9 million shares 2026-06-30 Source
Exact value

51926988 shares

Reported share-count change

157.56% · 31.8 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

20161073 shares · 2025-06-30· Source
51926988 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

4.22 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 795000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 3498000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 3150000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 1294000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 1779000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-107 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -15099000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -80400000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -40100000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -18331000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -33530000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-28.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -35800000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -24629000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -29600000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -35800000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -11000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -23700000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -11000000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

129 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 279000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 279000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 279000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 279000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 129000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-28.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -35800000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -24629000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -29600000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -35800000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -11000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -23700000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -11000000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 279000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 279000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 279000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 279000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 129000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-13.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: 3 of 11 periods available· newest 2025-12-31
Total liabilities: 3 of 11 periods available· newest 2025-12-31
Current assets: 3 of 11 periods available· newest 2025-12-31
Current liabilities: 3 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+436.5%

Prior period

USD 652,000

2024-01-01 – 2024-12-31
Current period

USD 3.5 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

3498000 − 652000 = 2846000 USD

652000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
3498000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Camp4 Therapeutics Corp · 2025-12-31 Camp4 Therapeutics Corp (edgar:1736730) Year-over-year change in Revenue: 2846000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 3498000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1154431 Filing: 000173673026000016 Input fundies:Revenue: 652000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1155193 Filing: 000173673026000016
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 28.61 million

Prior period

−USD 51.79 million

2024-01-01 – 2024-12-31
Current period

−USD 80.4 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-80400000 − -51791000 = -28609000 USD

-51791000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-80400000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Camp4 Therapeutics Corp · 2025-12-31 Camp4 Therapeutics Corp (edgar:1736730) Year-over-year change in Net income: -28609000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -80400000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1316150 Filing: 000173673026000016 Input fundies:NetIncome: -51791000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1250238 Filing: 000173673026000016
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 15.96 million

Prior period

−USD 45.56 million

2024-01-01 – 2024-12-31
Current period

−USD 29.6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-29600000 − -45562000 = 15962000 USD

-45562000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-29600000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Camp4 Therapeutics Corp · 2025-12-31 Camp4 Therapeutics Corp (edgar:1736730) Year-over-year change in Operating cash flow: 15962000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -29600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1316348 Filing: 000173673026000016 Input fundies:OperatingCashFlow: -45562000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1270547 Filing: 000173673026000016
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-36.7%

Prior period

USD 441,000

2024-01-01 – 2024-12-31
Current period

USD 279,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

279000 − 441000 = -162000 USD

441000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
279000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Camp4 Therapeutics Corp · 2025-12-31 Camp4 Therapeutics Corp (edgar:1736730) Year-over-year change in Capital expenditure: -162000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 279000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1271926 Filing: 000173673026000016 Input fundies:CapitalExpenditure: 441000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1272485 Filing: 000173673026000016
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 3.5 million 100% of revenue
Operating costs Derived USD 56.05 million 1,602% of revenue
Operating income −USD 52.56 million −1,502% of revenue
Tax, interest and other Derived USD 27.85 million 796% of revenue
Net income −USD 80.4 million −2,298% of revenue

Cash

Operating cash flow −USD 29.6 million −846% of revenue
Capital expenditure USD 279,000 8% of revenue
Free cash flow Derived −USD 29.88 million −854% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 Operating loss: operating costs were 14,923% of revenue.
2024 Operating loss: operating costs were 8,242% of revenue.
2025 Operating loss: operating costs were 1,602% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	350000	52229000 Derived	-51879000	-2588000 Derived	-49291000	-44833000 Derived	Source 2023-01-01 – 2023-12-31: 350000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -51879000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -49291000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -44155000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 678000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	652000	53740000 Derived	-53088000	-1297000 Derived	-51791000	-46003000 Derived	Source 2024-01-01 – 2024-12-31: 652000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -53088000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -51791000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -45562000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 441000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	3498000	56053000 Derived	-52555000	27845000 Derived	-80400000	-29879000 Derived	Source 2025-01-01 – 2025-12-31: 3498000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -52555000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -80400000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -29600000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 279000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 3.5M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Revenue	350000	Revenue: 350000 Open source
20242024-12-31	Revenue	652000	Revenue: 652000 Open source
20252025-12-31	Revenue	3498000	Revenue: 3498000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

436.5% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 350000 Open source
20242024-12-31	Year over year	86.3%	Revenue: 652000 Open source Revenue: 350000 Open source
20252025-12-31	Year over year	436.5%	Revenue: 3498000 Open source Revenue: 652000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,502.4% 2025

Net margin -2,298.5% 2025

Free cash flow margin -854.2% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	-14,822.6%	Operating Income: -51879000 Open source Revenue: 350000 Open source
20242024-12-31	Operating margin	-8,142.3%	Operating Income: -53088000 Open source Revenue: 652000 Open source
20252025-12-31	Operating margin	-1,502.4%	Operating Income: -52555000 Open source Revenue: 3498000 Open source
20232023-12-31	Net margin	-14,083.1%	Net Income: -49291000 Open source Revenue: 350000 Open source
20242024-12-31	Net margin	-7,943.4%	Net Income: -51791000 Open source Revenue: 652000 Open source
20252025-12-31	Net margin	-2,298.5%	Net Income: -80400000 Open source Revenue: 3498000 Open source
20232023-12-31	Free cash flow margin	-12,809.4%	Revenue: 350000 Open source Operating Cash Flow: -44155000 Open source Capital Expenditure: 678000 Open source
20242024-12-31	Free cash flow margin	-7,055.7%	Revenue: 652000 Open source Operating Cash Flow: -45562000 Open source Capital Expenditure: 441000 Open source
20252025-12-31	Free cash flow margin	-854.2%	Revenue: 3498000 Open source Operating Cash Flow: -29600000 Open source Capital Expenditure: 279000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -29.6M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Operating cash flow	-44155000	Operating Cash Flow: -44155000 Open source
20242024-12-31	Operating cash flow	-45562000	Operating Cash Flow: -45562000 Open source
20252025-12-31	Operating cash flow	-29600000	Operating Cash Flow: -29600000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -29.9M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Free cash flow	-44833000	Operating Cash Flow: -44155000 Open source Capital Expenditure: 678000 Open source
20242024-12-31	Free cash flow	-46003000	Operating Cash Flow: -45562000 Open source Capital Expenditure: 441000 Open source
20252025-12-31	Free cash flow	-29879000	Operating Cash Flow: -29600000 Open source Capital Expenditure: 279000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

59.5% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Liabilities / assets	30.1%	Total Liabilities: 16529000 Open source Total Assets: 54946000 Open source
20242024-12-31	Liabilities / assets	19.4%	Total Liabilities: 15163000 Open source Total Assets: 78307000 Open source
20252025-12-31	Liabilities / assets	59.5%	Total Liabilities: 70104000 Open source Total Assets: 117808000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.35× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Current assets / current liabilities	5.13×	Current Assets: 40013000 Open source Current Liabilities: 7807000 Open source
20242024-12-31	Current assets / current liabilities	6.92×	Current Assets: 66383000 Open source Current Liabilities: 9598000 Open source
20252025-12-31	Current assets / current liabilities	7.35×	Current Assets: 114095000 Open source Current Liabilities: 15514000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	−USD 49.29 million Exact value Exact value: -49291000 USD 2023-01-01 – 2023-12-31: -49291000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Camp4 Therapeutics Corp · 2023-12-31 Camp4 Therapeutics Corp (edgar:1736730) Net Income: -49291000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -49291000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000022/camp-20241231.htm#1722551 Filing: 000173673025000022 The citation records this snapshot. The page link may show a newer release later.	−USD 44.16 million Exact value Exact value: -44155000 USD 2023-01-01 – 2023-12-31: -44155000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Camp4 Therapeutics Corp · 2023-12-31 Camp4 Therapeutics Corp (edgar:1736730) Operating Cash Flow: -44155000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44155000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000022/camp-20241231.htm#1328695 Filing: 000173673025000022 The citation records this snapshot. The page link may show a newer release later.	USD 678,000 Exact value Exact value: 678000 USD 2023-01-01 – 2023-12-31: 678000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Camp4 Therapeutics Corp · 2023-12-31 Camp4 Therapeutics Corp (edgar:1736730) Capital Expenditure: 678000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 678000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000022/camp-20241231.htm#1330653 Filing: 000173673025000022 The citation records this snapshot. The page link may show a newer release later.	−USD 44.83 million Calculation and evidence -44155000 − 678000 USD Exact free cash flow: -44833000 USD 2023-01-01 – 2023-12-31: -44155000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 678000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Camp4 Therapeutics Corp · 2023-12-31 Camp4 Therapeutics Corp (edgar:1736730) Free cash flow: -44833000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44155000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000022/camp-20241231.htm#1328695 Filing: 000173673025000022 Input fundies:CapitalExpenditure: 678000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673025000022/camp-20241231.htm#1330653 Filing: 000173673025000022 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 51.79 million Exact value Exact value: -51791000 USD 2024-01-01 – 2024-12-31: -51791000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Camp4 Therapeutics Corp · 2024-12-31 Camp4 Therapeutics Corp (edgar:1736730) Net Income: -51791000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51791000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1250238 Filing: 000173673026000016 The citation records this snapshot. The page link may show a newer release later.	−USD 45.56 million Exact value Exact value: -45562000 USD 2024-01-01 – 2024-12-31: -45562000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Camp4 Therapeutics Corp · 2024-12-31 Camp4 Therapeutics Corp (edgar:1736730) Operating Cash Flow: -45562000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -45562000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1270547 Filing: 000173673026000016 The citation records this snapshot. The page link may show a newer release later.	USD 441,000 Exact value Exact value: 441000 USD 2024-01-01 – 2024-12-31: 441000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Camp4 Therapeutics Corp · 2024-12-31 Camp4 Therapeutics Corp (edgar:1736730) Capital Expenditure: 441000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 441000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1272485 Filing: 000173673026000016 The citation records this snapshot. The page link may show a newer release later.	−USD 46 million Calculation and evidence -45562000 − 441000 USD Exact free cash flow: -46003000 USD 2024-01-01 – 2024-12-31: -45562000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 441000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Camp4 Therapeutics Corp · 2024-12-31 Camp4 Therapeutics Corp (edgar:1736730) Free cash flow: -46003000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -45562000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1270547 Filing: 000173673026000016 Input fundies:CapitalExpenditure: 441000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1272485 Filing: 000173673026000016 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 80.4 million Exact value Exact value: -80400000 USD 2025-01-01 – 2025-12-31: -80400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Camp4 Therapeutics Corp · 2025-12-31 Camp4 Therapeutics Corp (edgar:1736730) Net Income: -80400000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -80400000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1316150 Filing: 000173673026000016 The citation records this snapshot. The page link may show a newer release later.	−USD 29.6 million Exact value Exact value: -29600000 USD 2025-01-01 – 2025-12-31: -29600000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Camp4 Therapeutics Corp · 2025-12-31 Camp4 Therapeutics Corp (edgar:1736730) Operating Cash Flow: -29600000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1316348 Filing: 000173673026000016 The citation records this snapshot. The page link may show a newer release later.	USD 279,000 Exact value Exact value: 279000 USD 2025-01-01 – 2025-12-31: 279000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Camp4 Therapeutics Corp · 2025-12-31 Camp4 Therapeutics Corp (edgar:1736730) Capital Expenditure: 279000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 279000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1271926 Filing: 000173673026000016 The citation records this snapshot. The page link may show a newer release later.	−USD 29.88 million Calculation and evidence -29600000 − 279000 USD Exact free cash flow: -29879000 USD 2025-01-01 – 2025-12-31: -29600000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 279000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Camp4 Therapeutics Corp · 2025-12-31 Camp4 Therapeutics Corp (edgar:1736730) Free cash flow: -29879000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1736730?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1316348 Filing: 000173673026000016 Input fundies:CapitalExpenditure: 279000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000016/camp-20251231.htm#1271926 Filing: 000173673026000016 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

13 filings · 822 latest values · 822 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001736730, 1736730, CAMP, edgar:1736730

Also known as CAMP4 THERAPEUTICS CORPORATION, CAMP4 Therapeutics Corporation, Camp4 Therapeutics Corp

Camp4 Therapeutics Corp

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation